Journal of Cachexia, Sarcopenia and Muscle
 The Author(s) 2012
10.1007/s13539-012-0057-7

Letter to the Editor

Comment on Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats

Nima Alamdari1 and Per-Olof HasselgrenContact Information

(1)  Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA

Contact Information Per-Olof Hasselgren
Email: phasselg@bidmc.harvard.edu

Received: 4 December 2011  Accepted: 21 December 2011  Published online: 23 February 2012


Without Abstract
This comment refers to the article available at: http://dx.doi.org/10.1007/s13539-011-0018-6.

Dear Sir,

We read with interest the recent article by Toledo et al. [1]. In their study, the authors found that mRNA levels for SIRT1 were increased in muscle from tumor-bearing rats and that SIRT3 mRNA levels were unchanged. In the discussion of the results, the authors stated that the observation of unchanged SIRT3 “is in contrast with that of Alamdari et al. [39] showing an upregulation of SIRT3 in skeletal muscle during sepsis”. This was a surprising statement since we did not examine or report on SIRT3 expression in our study [2]. We did examine the effects of sepsis on the mRNA levels for the histone deacetylases HDAC3 and 6 and nuclear protein levels for the same HDACs as well as for SIRT1. Importantly, protein levels for HDAC6 and SIRT1 were decreased (not increased) and muscle HDAC activity was reduced during sepsis.

We think the misquotation of our work in the article by Toledo et al. [1] was unfortunate, not only because it was erroneous but also because it suggests that the expression of a histone deacetylase (SIRT3) may be increased during sepsis, implying increased deacetylase activity and reduced levels of acetylated cellular proteins. This is opposite to the conclusions in our paper [2] and in other recent reports from our laboratory [37] in which we found evidence that muscle wasting caused by sepsis and glucocorticoids is associated with, and probably at least in part regulated by increased acetylation of cellular proteins. These conclusions were also supported by experiments in which treatment of cultured muscle cells [4] or rats in vivo [2] with histone deacetylase inhibitor increased the expression of atrogin-1 and stimulated protein breakdown. In more recent experiments, we found evidence for a role of reduced (not increased) SIRT1 expression and activity in glucocorticoid-induced muscle wasting [7]. It was surprising to see that SIRT1 mRNA levels were increased in muscle from tumor-bearing rats in the study by Toledo et al. [1]. It would have been interesting to have information about SIRT1 protein levels and HDAC activity in the same muscles.

Sincerely,

Nima Alamdari,

Per-Olof Hasselgren

Acknowledgments  The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle [8].
Open Access  
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.


References

1. Toledo M, Busquets S, Ametller E, Lopez-Soriano FJ, Argiles JM. Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration? J Cachexia Sarcopenia Muscle. 2011;2:57–62.
PubMed SpringerLink
 
2. Alamdari N, Smith IJ, Aversa Z, Hasselgren PO. Sepsis and glucocorticoids upregulate p300 and downregulate HDAC6 expression and activity in skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2010;299:R509–20.
PubMed CrossRef ChemPort
 
3. Yang H, Menconi MJ, Wei W, Petkova V, Hasselgren PO. Dexamethasone upregulates the expression of the nuclear cofactor p300 and its interaction with C/EBPbeta in cultured myotubes. J Cell Biochem. 2005;94:1058–67.
PubMed CrossRef ChemPort
 
4. Yang H, Wei W, Menconi M, Hasselgren PO. Dexamethasone-induced protein degradation in cultured myotubes is p300/HAT dependent. Am J Physiol Integr Comp Physiol. 2007;292:R337–44.
CrossRef ChemPort
 
5. Hasselgren PO. Ubiquitination, phosphorylation, and acetylation—triple threat in muscle wasting. J Cell Physiol. 2007;213:679–89.
PubMed CrossRef ChemPort
 
6. Chamberlain W, Gonnella P, Alamdari N, Aversa Z, Hasselgren PO. Multiple muscle wasting-related transcription factors are acetylated in dexamethasone-treated muscle cells. Biochem Cell Biol. 2012. doi:10.1139/o11-082
 
7. Alamdari N, Aversa Z, Castillero E, Gurav A, Petkova V, Tizio S, Hasselgren PO. Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism. Biochem Biophys Res Commun. 2012;417:528–33.
PubMed CrossRef ChemPort
 
8. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8